Business context and reporting period
Filing identity discrepancy: The request metadata names Tvardi Therapeutics, Inc., but the supplied Form 10-Q is for Cara Therapeutics, Inc. This summary reflects the filing text provided. It covers the quarter and nine months ended September 30, 2015; financial statement amounts below are in millions of dollars unless noted.
Cara was a clinical-stage biopharmaceutical company developing kappa opioid receptor-targeting treatments for pain and pruritus. It had no products for sale; revenue primarily came from license and collaboration arrangements. The filing was signed November 9, 2015.
Financial and operating metrics
| Metric | Q3 2015 | Q3 2014 | Nine months 2015 | Nine months 2014 |
|---|---|---|---|---|
| Total revenue | $2.440 | $1.125 | $3.803 | $2.263 |
| Research and development expense | $5.584 | $6.208 | $13.653 | $11.609 |
| General and administrative expense | $1.865 | $1.520 | $5.609 | $4.390 |
| Operating loss | $(5.009) | $(6.603) | $(15.459) | $(13.736) |
| Net loss | $(4.787) | $(6.545) | $(15.160) | $(13.573) |
| Net loss per share, basic and diluted | $(0.19) | $(0.29) | $(0.64) | $(0.67) |
| Net cash used in operating activities | Not presented by quarter | $(17.310) | $(11.818) |
- Operating loss as a share of revenue was approximately 205% in Q3 2015 versus 587% in Q3 2014, and 407% for the first nine months of 2015 versus 607% in the comparable 2014 period. The filing does not report a conventional gross margin.
- At September 30, 2015, cash and cash equivalents were $111.116 million, restricted cash was $0.700 million, total current assets were $115.680 million, and total current liabilities were $3.374 million. The resulting current ratio was approximately 34.3x.
- Total assets were $117.897 million and stockholders’ equity was $113.863 million. The balance sheet reports no debt liability; it does report a $0.660 million deferred lease obligation. Operating lease commitments totaled $1.879 million.
- Cash increased $58.453 million in the first nine months, principally reflecting $75.776 million of financing cash flow, including net proceeds from the August follow-on offering. Investing cash outflow was $0.013 million.
Material changes versus the prior comparable period
- Revenue increased 117% in Q3 and 68% for the first nine months. The 2015 periods included milestone revenue, notably from Maruishi and CKD; these amounts are not product sales.
- Q3 operating expenses fell 4%, as lower clinical and manufacturing costs outweighed higher stock compensation and other R&D and administrative costs. Nine-month operating expenses rose 20%, including an 18% increase in R&D and a 28% increase in G&A.
- Q3 net loss narrowed to $4.787 million from $6.545 million, while the nine-month net loss widened to $15.160 million from $13.573 million. Nine-month operating cash use increased to $17.310 million from $11.818 million.
- Cash and cash equivalents rose from $52.663 million at December 31, 2014 to $111.116 million at September 30, 2015. The increase primarily followed a $75.231 million net follow-on offering completed in August. Shares outstanding increased to 27,231,583 from 22,802,039.
Outlook, management commentary, and risks
- Management estimated that September 30 cash would fund planned operating expenses and capital requirements through the end of Q3 2017, excluding potential future collaboration milestones. The company also cautioned that trial timing and costs could cause cash to be used sooner.
- Management expected continued losses and negative operating cash flows, with R&D spending expected to rise as development advanced. It said additional capital would be needed beyond existing cash and anticipated receipts, particularly to complete planned Oral CR845 development. Further financing could dilute shareholders, restrict operations, or require the company to delay or reduce programs.
- In September 2015, Cara initiated a Phase 3 adaptive trial of IV CR845 for postoperative pain; top-line results were expected in the first half of 2016. It planned additional Phase 3 trials in the first half of 2016. Oral CR845 entered a Phase 2a osteoarthritis trial, with top-line data expected by year-end 2015; a larger Phase 2b trial was planned for the first half of 2016, subject to results.
- After positive Phase 2 uremic-pruritus results, the company intended to consult the FDA on a potential pivotal trial and planned to seek breakthrough therapy and orphan drug designations. These were plans, not granted designations or approvals.
- In October 2015, Cara received approximately $1.725 million from Maruishi and $0.417 million from CKD for milestones earned in September. The filing also identifies potential future milestones, whose achievement and timing were uncertain.
- Principal risks included clinical and regulatory failure or delay, manufacturing and trial execution, competition, intellectual-property protection, dependence on collaborators and key personnel, commercialization and reimbursement uncertainty, and access to additional financing. No material legal proceedings or new risk factors were reported. Management stated disclosure controls were effective and reported no material change in internal control over financial reporting.
Important facts for investors to verify
- Confirm that Cara Therapeutics, Inc.—not Tvardi Therapeutics, Inc.—is the intended issuer and filing.
- Verify the stated cash runway assumptions against actual trial enrollment, development spending, and subsequent financing or collaboration receipts.
- Track clinical milestones and results for IV and Oral CR845, including whether planned trials began on schedule and whether the anticipated data were reported.
- Distinguish collaboration milestone and deferred revenue from recurring product revenue; the company had no products for sale and had received no collaboration royalties to date.
- Review the full filing and subsequent disclosures for changes to financing needs, share dilution, regulatory plans, and clinical or commercial risks.